PE Tech Report


Like this article?

Sign up to our free newsletter

InTandem Capital Partners closes Fund III at $715m

InTandem Capital Partners, a middle-market private equity firm focused on healthcare services, has held the final closing of InTandem Capital Partners Fund III, at $715m, above its original target of $650m.

As with predecessor funds, Fund III will make control investments in North American payor, provider, and pharmaceutical services businesses.

Fund III secured commitments from existing and new investors including endowments, foundations, family offices, healthcare and pension systems, and financial institutions.

The fund is already actively investing, having recently completed its third platform deal in Adams Clinical, a multi-site clinical research management organisation focused on late-stage outpatient central nervous system trials.

Kirkland and Ellis and Raymond James advised on Fund III.

Like this article? Sign up to our free newsletter